Drug profile

The FDA adverse-event record for Lidocaine Injection

41 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Lidocaine Injection. See the species affected, top reactions, and outcomes below.

41
adverse-event reports
22.0%
death-coded share
Dog
most-reported species
15
Other abnormal test result NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
41
Total Reports
9
Deaths Reported
22.0%
Death Rate

Active Ingredients

Lidocaine Injection

Administration Routes

ParenteralUnknownIntravenousOtherEpiduralIntra-Articular

Species Affected

Dog 32
Cat 9

Most Affected Breeds

Domestic Shorthair 5
Retriever - Labrador 4
Boxer (German Boxer) 4
Bulldog 3
Pit Bull 3
Crossbred Canine/dog 2
Chihuahua 2
Shepherd (unspecified) 2
Cat (unknown) 2
Corgi - Welsh Pembroke 1

Most Reported Reactions

Other abnormal test result NOS 15
Vocalisation 10
Lethargy (see also Central nervous system depression in 'Neurological') 10
Anorexia 10
Vomiting 9
Death by euthanasia 8
Hypothermia 6
Decreased appetite 6
Abnormal radiograph finding 6
Azotaemia 6
Not drinking 5
Not eating 5

Outcome Breakdown

Recovered/Normal
13 (31.7%)
Ongoing
9 (22.0%)
Outcome Unknown
8 (19.5%)
Euthanized
8 (19.5%)
Recovered with Sequela
2 (4.9%)
Died
1 (2.4%)

Lidocaine Injection Adverse Event Insights

41 reports name Lidocaine Injection; 9 recorded a death outcome (22.0% of reported events, not a population-level mortality rate). Active ingredient: Lidocaine Injection. Administration routes: Parenteral, Unknown, Intravenous, Other.

By species: Dog (32 reports), Cat (9 reports). By breed: Domestic Shorthair (5), Retriever - Labrador (4), Boxer (German Boxer) (4).

Leading clinical signs: Other abnormal test result NOS (15), Vocalisation (10), Lethargy (see also Central nervous system depression in 'Neurological') (10), Anorexia (10). Outcome, 41 coded reports: Recovered/Normal leads at 31.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.